Use of dynamic contrast enhanced time intensity curve shape analysis in MRI: theory and practice

Cristina Lavini¹
Maarten S Buiter²
Mario Maas¹
¹Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands; ²Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Abstract: The analysis of dynamic contrast enhanced data using the classification of the time intensity curve (TIC) shape is widely employed both in its region of interest and pixel by pixel variants. While its application in breast imaging is established and documented by a large amount of scientific works, its use for other body parts is still scattered and there is no consensus as to whether the method can be used alone to perform differential diagnosis in cancer or in inflammatory diseases. In this review we evaluate all the literature which makes use of TIC shape analysis in tissues other than breast, discuss the results, highlight the possible shortcomings, and suggest directions for future research.

Keywords: DCE-MRI, TIC shape, pattern recognition, review

Introduction

Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) is an important imaging technique used in radiology as an additional tool in oncology assessment. Its safety, repeatability, high spatial resolution, and the fact that it can be performed on clinical magnetic resonance imaging (MRI) scanners with standard specifications allow its application in routine clinical and research settings. The additional value of this technique, with respect to conventional static MR imaging sequences, lies in its ability to identify changes in tissue physiology when changes in the anatomy are not yet visible. In the last two decades it has become an established method, and it is now often performed as part of a routine MRI protocol.

Technically, DCE-MRI consists of a series of fast MRI scans, commonly available on all clinical scanners, which are acquired for a duration of 3 to 10 minutes while a gadolinium (Gd)-based contrast agent is injected intravenously. As the contrast medium flows from the blood pool into the tissue, the signal intensity on a T1-weighted image during and after the injection varies according to a pattern which is dependent on the vascularization and on the viability of the tissue to the contrast agent. This time dependent signal intensity or time intensity curve (TIC) in the tissues is recorded and further analyzed to provide several parameters useful for diagnosis.

The analysis of data generated by DCE-MRI is not fully standardized yet, and can roughly be divided into three general approaches: visual assessment of the TIC curves, parametric analysis of the time dependent MRI signal, and quantitative analysis using pharmacokinetic models (PKM).
Visual TIC shape assessment
A common approach in the analysis of DCE-MRI is to look at the dynamic data by selecting a region of interest (ROI) in the lesion and to observe how the average signal intensity of the ROI varies with time. Based on this observation, the radiologist can spot areas of vascular disruption, which are characterized by a quick signal uptake. This approach, although operator dependent, is widely used in routine clinical practice, especially in breast imaging. The visual assessment of the shape of the original TIC has some obvious advantages: it is easy to perform and it can be easily applied in daily clinical routine.

Parametric analysis of the signal enhancement
Parametric analysis involves the generation of parameters describing the original DCE-MRI signal intensities, such as the maximum enhancement (ME), rate of enhancement, time to peak, initial area under the curve, etc. It can be calculated on a pixel by pixel (or more strictly speaking, voxel by voxel) basis and rendered in parametric images. Several commercially available software packages allow this type of analysis. Unfortunately, the calculated parameters are dependent on the MRI protocol chosen and are not quantitative, i.e., they are not a measure of intrinsic physiological properties. The parameters used in the T1-w MR sequence, e.g., the repetition time (TR) and flip angle, significantly affect the relationship between the amount of contrast agent in the tissue and the signal intensity change. As a result, the same amount of Gd uptake in the tissue might result in significantly varying relative signal change in differently weighted MR sequences, as nicely exemplified by Evelhoch.1 The technique is, therefore, not suited to comparing disease activity across patients in clinical studies.

PKM
Quantification of the DCE-MRI data can be achieved by means of PKM based analysis.2 The application of the theoretical PKM to the DCE-MRI data (through parameter fitting) permits the extraction of physiologically relevant quantities that reflect intrinsic properties of the tissue, such as \( v_e \) (the extracellular extravascular space), \( K_{\text{trans}} \) (the forward transfer coefficient of Gd between plasma and \( v_e \)), and \( v_v \) (the vascular volume). Nowadays, this is an established method which has gained trust and popularity among scientists for its ability to grade cancer, and to assess neoangiogenesis and the effect of drugs.3,4 Unlike most MRI based techniques, it is (or it strives to be) quantitative, i.e., it measures intrinsic properties of the tissue. However, the very complex implementation of PKM, as well as its considerable propensity for errors, has made it very challenging to apply it in clinical practice. Examples of these challenges include the fact that the model requires the knowledge of the absolute tissue contrast agent concentration, whose calculation requires the measurement of the native T1 maps, as well as knowledge of the arterial input function (AIF), a fundamental input of the model. Moreover, the accurate sampling of the vascular signal used to generate the AIF puts some strict constraints on the minimal temporal resolution of the dynamic scan.5

In this review we will concentrate on the methods based on (or derived from) the first of these three aforementioned analysis approaches, and we refer to that as the “TIC shape analysis.”

TIC shape analysis
Since the introduction of DCE-MRI in breast imaging,6 radiologists have observed and classified a number of enhancement shape types in various pathologies (Figure 1). In DCE-MRI of the breast, the dynamic scan consists of a few dynamic scans (usually three), each scan being repeated every 90 seconds.7 The difference between the various shapes is found in the different slopes of the line connecting the three points in the image (Figure 1A). In other body parts, the dynamic scans are usually acquired with a higher temporal resolution, and the shapes of the TIC can vary across a wider range of patterns (Figure 1).8-9 The TICs are usually obtained from a selected ROI, encompassing the whole or a part of the lesion.

Although not an absolute measure of permeability, the shape of the uptake curve of a dynamic scan is a reflection of the tissue viability and permeability to the contrast agent; the rise in contrast enhancement reflects (indirectly) the transfer of the contrast agent from the capillary to the extravascular space, from which the agent is later reabsorbed by the blood pool, resulting, eventually, in a signal decrease. This increasing–decreasing pattern reflecting higher capillary permeability can be observed within the typical duration of the DCE-MRI scan (5–10 minutes). Areas of lower perfusion and permeability tend to enhance in a much slower fashion, and the signal does not decrease until after the end of the DCE-MRI scan. The use of these features to make clinical decisions has led many authors to identify TIC shapes (up to seven) in the analyzed tissues and to investigate their value as a potential diagnostic feature.9-11

This straightforward approach, sometimes described as heuristic (i.e., obtained by exploration of possibilities rather
than by following set rules) might lack precision and not be a quantitative measure of physiological properties, yet the number of articles using the TIC shape as a potential mirror of disease seems indeed to have grown in recent years, although predominantly in breast imaging.

Furthermore, in the last 6 years, a new line of research has taken root, ie, redeveloping the heuristic shape analysis method into something more robust, less user dependent, less MRI protocol dependent, and image-wise, enough advancement to compete with other more quantitative methods.

Instead of an ROI dependent evaluation of averaged TICs, the TICs are analyzed in a pixel by pixel (or voxel by voxel) fashion, in every single voxel acquired by the DCE-MRI scan sequence. This method is proposed to overcome the intrinsic insensitivity to spatial heterogeneity of the ROI based analysis. As large lesions, whether cancerous or inflammatory, are not homogeneous, sampling and averaging signals from the ROIs to look at the dynamic course of the TIC misses important characteristics of the lesion. The pixel by pixel computer assisted analysis is done using different algorithms and its results are rendered in a color coded map (Figure 2).

It is the purpose of this review to present the results of works using the TIC shape as an endpoint parameter for the determination of disease. Studies where the TIC is described but not used as the main decision making tool have been omitted. Studies have been selected with a similar DCE-MRI protocol.
protocol in terms of scan duration and acquisition frequency. Because the shape does depend on the time window used (all the TICs will present with a washin and washout phase if scanning time is long enough), we limited the analysis to protocols with a minimum acquisition time of 2.5 minutes, and a maximum interval between the dynamic scans of 30 seconds.

Furthermore, although the literature about TIC shape in breast MRI is very extensive (breast was the first application of TIC shape analysis in DCE-MRI) and outnumbers by far the literature of TIC shape analysis in other pathologies, the largest part of the literature refers to dynamic data acquired with a low temporal sampling rate (the three point measurement\textsuperscript{11,14-17} where only three time points are acquired to favor spatial resolution). For this reason, in this review they are excluded from the analysis. A good overview of DCE-MRI methods in the breast can be found in Turnbull.\textsuperscript{18}

**Review of clinical applications**

An overview of the articles making use of TIC shape analysis and their results is shown in Table 1. The articles reviewed were first selected using broad search term queries in PubMed (search term [all fields]: DCE-MRI). Exclusion criteria were: breast DCE-MRI, use of PKM, use of quantitative or semiquantitative analysis methods, and time resolution of the DCE-MRI scan >30 seconds. Articles were further selected by manually searching if the authors presented a TIC shape type focused analysis.

Applications of the technique encompass a large range of diseases and anatomy, from tumors to arthritis, from brain to musculoskeletal, rectum, liver, brain, parotid glands, etc.

A problem when comparing literature describing TIC shapes is that almost all studies use their own classification and naming of TIC shapes (see Figure 1B and C for examples).

As the number of classes (varying from 2 to 7) and classification names are not consistent across publications (see Figure 1), to simplify reading, we will use in this review the following two letter nomenclature, in which the first and second letter represents, respectively, the initial and the final behavior of the DCE-MRI uptake curve, and where upper and lower case letter represent, respectively, a growing and a decreasing pattern (S or s = slow, F or f = fast, P = plateau, O = absence of uptake) (Figure 3).

In some articles, type FF is (sub) divided into two groups, depending on the velocity of the upswing. In this review we will call them Ff1 and Ff2 (Ff1 = slower washin and Ff2 = faster washin).

Regarding the choice of classes, from the overview in Table 1, it can be seen that TIC types SS and FF are used in most studies (26 and 28 of 29 studies, respectively), followed by FP which is found in 21 of 29 studies. In 19 of 29 studies, type O (nonenhancing) is used, and 15 of 29 studies use type FS. Type X (enhancing but with unidentified shape) is only used by Lavini et al\textsuperscript{12,23} Type V is identified by Lavini et al\textsuperscript{12,23} and Eida et al.\textsuperscript{26} However, Eida et al\textsuperscript{26} describes the shape, but does not attribute it to a vascular signal. In Figure 2, this shape as identified by Eida et al\textsuperscript{26} has been described as Ff2. Also, Yabuuchi et al\textsuperscript{27} and Sasaki et al\textsuperscript{24} differentiated between fast and slow washout type Ff TICs (Ff1 and Ff2). Eida et al\textsuperscript{26} classified as type O (as in their TIC shape illustration) everything which is not classified as SS, Ff, and V. The overview shows, on the one hand, the wide application of this technique in terms of pathologies, but also at the same time, the plethora of different classification types and conclusions.

**TIC analysis methods: ROI versus pixel by pixel**

Early works using TIC shape analysis were ROI based: a ROI was drawn by the radiologist on a suspected area, and the TIC derived from an averaged signal. Despite the general expectation that most malignant lesions tended to present a fast enhancing TIC (whereas benign lesions enhance slowly), a large overlap on the shape types across lesions was observed,\textsuperscript{19} suggesting a poor positive and negative predictive value of the TICs.

This lack of reproducibility could be attributed to various reasons. The fact that the analysis is based on an ROI, arbitrarily chosen by a radiologist on the basis of a native T1-w or postcontrast T1-w image, could result not only in subjectivity in the ROI choice, but also in signal averaging over the ROI. The information on the heterogeneity of the lesion in terms of TIC shapes was, therefore, lost.

To overcome these limitations, a new approach was proposed independently by Kubassova et al\textsuperscript{25} and by Lavini et al\textsuperscript{12} where the TICs were analyzed on a pixel by pixel basis. Other similar approaches have been proposed by others, such as Eida et al\textsuperscript{26} and Yuan et al\textsuperscript{13}, who added the ME information by means of a color hue in a fashion similar to that used for breast imaging by Preim et al\textsuperscript{17} and by Sasaki et al.\textsuperscript{24} In these works, every single pixel is assigned to a specific TIC shape (according to some predefined classes) by means of a computer aided pattern recognition (PR) method and the result rendered in color coded maps. The classification is usually done by using thresholds on the various features identified to describe the TIC shape, such as the initial slope,
Table 1 Overview of studies using the time intensity curve shape for clinical diagnosis

<table>
<thead>
<tr>
<th>Study</th>
<th>Body part/number of patients</th>
<th>Temporal resolution/duration</th>
<th>Disease</th>
<th>TIC shapes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van der Woude et al</td>
<td>Extremities/175 patients</td>
<td>1.5–3 sec/5 min</td>
<td>Benign and malignant MSK tumors: GCT, ABC, chondroblastoma, osteoblastoma, myxoid liposarcoma, schwannoma, chondromatosis, osteoid osteoma</td>
<td>FP, Ff, FS, SS</td>
<td>Type Ff or FP was seen on 44/45 malignant bone tumors, on 19/22 soft tissue sarcomas, on 6/26 low grade malignant tumors, and on 25/50 benign bone tumors. Some benign tumors (ABC, GCT, chondroblastoma, dysplasia, and abscess) showed early enhancement (FP of Ff). 25/50 benign soft tissue tumors show type SS. 175 patients with an MSK tumor, no statistical difference between malignant and benign bone tumors.</td>
</tr>
<tr>
<td>Hawighorst et al</td>
<td>Extremities/N/A</td>
<td>5–30 sec, 3–5 min</td>
<td>GCT, ABC, osteomyelitis (meta-analysis)</td>
<td>FP, Ff, V</td>
<td>GCT: type Ff and FS; ABC and osteomyelitis: type FP.</td>
</tr>
<tr>
<td>Verstraete et al</td>
<td>Lower extremities/N/A</td>
<td>N/A</td>
<td>Various MSK tumors</td>
<td>SS, FS, Ff</td>
<td>Myeloma, high grade sarcoma, GCT: type Ff. Benign and malignant MSK masses: type FS. Myxoma, enchondroma, cavernous hemangioma, and muscle: type SS.</td>
</tr>
<tr>
<td>van Rijswijk et al</td>
<td>Upper and lower extremities/10 patients</td>
<td>3 sec/5 min</td>
<td>Synovial sarcoma</td>
<td>O, SS, FS, FP, Ff</td>
<td>Most synovial sarcoma displayed some areas of fast enhancement (FS, FP, Ff). One displayed type SS.</td>
</tr>
<tr>
<td>Tokuda et al</td>
<td>Vertebrae/34 patients</td>
<td>1 sec/2.5 min</td>
<td>Pathologic compression, osteoporosis, metastases</td>
<td>O, SS, FS, FP, Ff</td>
<td>Osteoporosis: FP (8); Benign lesion: FP (7), Ff (1), B (3); metastatic: SS (2), FP (15), Ff (1), FS (3).</td>
</tr>
<tr>
<td>Kawakami et al</td>
<td>Bone/49 patients</td>
<td>13 sec/5 min</td>
<td>Malignant: fibrous histiocytoma, osteosarcoma, Ewing sarcoma, chondrosarcoma, chordoma. Benign: GCT, ABC, chondroblastoma, fibroma, enchondroma, fibrous dysplasia, osteofibrous dysplasia</td>
<td>O, SS, FP, Ff</td>
<td>Pooled results: malignant (22): O(0), SS(4), Ff (17); benign (27): O (0), SS (17), Ff (6). Malignant bone tumors show a higher slope than benign tumors. GCT had a relatively higher slope. Malignant lesions: FP. Benign lesions: SS.</td>
</tr>
<tr>
<td>Lavini et al</td>
<td>Chondrosarcoma/13 patients</td>
<td>20 sec/7 min</td>
<td>Chondrosarcoma, enchondroma</td>
<td>O, SS, Ff, P, FS, V, X</td>
<td>Prevalence of SS in chondrosarcoma, but Ff, FP, and FS always present in different amounts. Enchondroma mainly type SS.</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Body part/number of patients</th>
<th>Temporal resolution/duration</th>
<th>Disease</th>
<th>TIC shapes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yuan et al²³</td>
<td>Head and neck/23 patients</td>
<td>2.6 sec/8 min</td>
<td>Untreated HNSCC</td>
<td>SS, Ff1, Ff2, FS, V + hue to render ME</td>
<td>Classification based on predominance of one type. Tumors predominantly Ff. Majority of primary tumors presented more than 90% presence of type Ff, the same as salivary glands, tonsils, and thyroid. Metastatic nodes present with various combinations of TIC shapes and grading. Muscle has a prevalence of SS.</td>
</tr>
<tr>
<td>Sasaki et al²⁴</td>
<td>Head and neck/44 patients</td>
<td>3 min/10 sec</td>
<td>Sinonasal diseases (organized hematoma, fungal rhinosinusitis, malignant lymphoma)</td>
<td>O, SS, FP, Ff1, Ff2</td>
<td>Benign lesions present types O, SS, and Ff. Malignant tumors contain types Ff and O. Differentiation of benign from malignant cannot be based on TIC pattern alone.</td>
</tr>
<tr>
<td>Lavini et al²⁵</td>
<td>Brain/Brain/15 patients</td>
<td>13 sec/7 min</td>
<td>High grade glioma and effect of antiangiogenic agents</td>
<td>O, SS, Ff, FS, FP, V</td>
<td>Prevalence of type SS in all gliomas. Type Ff, FP, and FS present in various amounts. TIC shape is not predictive of effect of antiangiogenic agent.</td>
</tr>
<tr>
<td>Eida et al²⁶</td>
<td>Salivary gland/36 patients</td>
<td>10 sec/3 min</td>
<td>Benign tumors: pleomorphic adenomas, Warthin tumors, myoepitheloma Malignant tumors: salivary duct carcinoma, adenocarcinoma, adenoid cystic carcinoma, malignant lymphoma</td>
<td>O, SS, Ff1, Ff2, V</td>
<td>Total tumor area. Pleomorphic adenoma: SS (14/14); Warthin: Ff2 (8/8); malignant (12); prevalence of type Ff. Malignant lymphomas homogeneously type Ff2 [3/3]. Adenoid cystic carcinoma: SS (2/2). Type Ff2 consistent with tumor hypercellularity (densely packed lymphoma cells). Type SS correlates with dense fibrous tissue.</td>
</tr>
<tr>
<td>Yabuuchi et al²⁷</td>
<td>Parotid gland/47 patients</td>
<td>30 sec/5 min</td>
<td>Tumors (Warthin tumors), pleomorphic adenoma, carcinoma</td>
<td>O, SS, Ff1, Ff2</td>
<td>O, SS is found in benign pleomorphic adenomas. Warthin tumor: type Ff1, Ff2, or O. Carcinoma: type Ff1. Combined analysis with DWI.</td>
</tr>
<tr>
<td>Schaefer et al²⁸</td>
<td>Lung/36 patients</td>
<td>10 sec/4 min</td>
<td>Solitary pulmonary nodules. Malignant (adenocarcinoma, squamous cell carcinoma, carcinoid, metastasis). Benign (hamartoma, inflammatory lesion)</td>
<td>O, SS, FP, Ff</td>
<td>Malignant nodules: Ff (all), FP (9/13); benign lesions: SS (8/16), FP (4/16), O (4/16); hamartoma: type FP; inflammatory: type SS.</td>
</tr>
<tr>
<td>Donmez et al²⁹</td>
<td>Lung/40 patients</td>
<td>N/A</td>
<td>Solitary pulmonary nodules (cancer, tuberculomas, aspergillomas)</td>
<td>SS, FP, Ff</td>
<td>Malignant lesions: Ff (all but one). Benign lesions: SS (10) or FP (10).</td>
</tr>
<tr>
<td>Kono et al³⁰</td>
<td>Lung/202 patients</td>
<td>1 min/8 min</td>
<td>Solitary pulmonary nodules (tuberculoma, hamartoma, tuberculosis, pneumonia)</td>
<td>SS, FP, Ff</td>
<td>Lung cancer: Ff, pneumonia: FP; tuberculoma: SS; hamartoma: SS.</td>
</tr>
<tr>
<td>Yamashita et al³¹</td>
<td>Liver/384 patients</td>
<td>30 sec/3.5 min</td>
<td>Hepatoma, metastasis, cholangiocarcinoma, adenoma, FNH, hemangioma, abscess, cyst</td>
<td>O, SS, Ss, Ff</td>
<td>Hepatoma: prevalence of Ff; cholangiocarcinoma: SS, Ss, Ff; cyst: O; hemangioma: prevalence of SS; metastasis: O, SS, Ss, Ff.</td>
</tr>
<tr>
<td>Wang et al³²</td>
<td>Liver/7 patients</td>
<td>Respiration triggered</td>
<td>HCC treated with antiangiogenic agents</td>
<td>FP, Ff, FS</td>
<td>TIC tumor distribution: Ff (4/7), FS (3/). TIC parenchymal distribution: FS (6/7), FP (1). After treatment no changes in TIC distribution.</td>
</tr>
<tr>
<td>Study</td>
<td>Region</td>
<td>Patients</td>
<td>Imaging</td>
<td>Time</td>
<td>Disease(s)</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>----------</td>
<td>---------</td>
<td>------</td>
<td>------------</td>
</tr>
<tr>
<td>Tuncbilek et al. [13]</td>
<td>Colon/rectum</td>
<td>21 patients</td>
<td>3D, 40 sec/4 min</td>
<td>colorectal carcinomas</td>
<td>O, SS, C, Ff</td>
</tr>
<tr>
<td>Noworolski et al. [14]</td>
<td>Prostate</td>
<td>25 patients</td>
<td>1.5 sec/9 min</td>
<td>Tumors</td>
<td>SS, FP, Ff</td>
</tr>
<tr>
<td><strong>TIC shapes in inflammatory diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lavini et al. [12]</td>
<td>Musculoskeletal</td>
<td>4 patients</td>
<td>3D, 20 sec/7 min</td>
<td>Arthritis, osteoblastoma, chondrosarcoma</td>
<td>O, SS, FP, Ff, FS, V, X</td>
</tr>
<tr>
<td>Kubassova et al. [15]</td>
<td>Metacarpophalangeal joints</td>
<td>10 patients</td>
<td>3D, 7 sec/2.3 min</td>
<td>Rheumatoid arthritis</td>
<td>O, SS, FP, Ff</td>
</tr>
<tr>
<td>van der Leij et al. [16]</td>
<td>Knee</td>
<td>5 patients</td>
<td>3D, 20 sec/7 min</td>
<td>Synovitis</td>
<td>O, SS, Ff, FS, FP, V</td>
</tr>
<tr>
<td>van de Sande et al. [17]</td>
<td>Knee</td>
<td>28 patients</td>
<td>3D, 20 sec/7 min</td>
<td>Early RA and non RA (UA, crystal arthritis, spondylarthritis) patients</td>
<td>O, SS, Ff, FS, FP, V</td>
</tr>
<tr>
<td>Kim et al. [18]</td>
<td>Hips</td>
<td>18 patients</td>
<td>3D, 30 sec/6 min</td>
<td>Arthritis, synovitis</td>
<td>Ff1 and Ff2 classification based on left/right asymmetry</td>
</tr>
<tr>
<td>Giusti et al. [19]</td>
<td>Upper abdomen</td>
<td>53 patients</td>
<td>25 sec/6.5 min (respiration triggered)</td>
<td>CD</td>
<td>O, SS, Ff, FS, FP, Ss</td>
</tr>
<tr>
<td>Ziech et al. [20]</td>
<td>Abdomen</td>
<td>33 patients</td>
<td>3D, 0.82 sec/6 min</td>
<td>CD</td>
<td>O, SS, Ff, FS, FP, V</td>
</tr>
<tr>
<td>Ziech et al. [21]</td>
<td>Lower abdomen</td>
<td>16 patients</td>
<td>3D, 4.2 sec/3 min</td>
<td>Fistulas (in CD). Anti-TNF alpha therapy</td>
<td>O, SS, Ff, FS, FP, V</td>
</tr>
<tr>
<td>Horsthuis et al. [22]</td>
<td>Lower abdomen</td>
<td>16 patients</td>
<td>2D, 5 sec/6 min</td>
<td>Fistulas</td>
<td>O, SS, FP, Ff, FS, FP, X, V</td>
</tr>
</tbody>
</table>

**Notes:** When describing the time intensity curve shape, the first and second letter represents the initial and the final behavior of the curve, respectively. The upper and lower case letter represents a growing and a decreasing pattern, respectively. F or f, fast; S or s, slow; P, plateau; O, absence of uptake; V, vascular.

**Abbreviations:** ABC, aneurysmal bone cyst; CD, Crohn's disease; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein; DWI, diffusion weighted imaging; GCT, giant cell tumor; FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; ME, maximum enhancement; min, minutes; MSK, musculoskeletal; MVD, microvessel density; N/A, not available; PDAI, Perianal Disease Activity Index; RA, rheumatoid arthritis; ROI, region of interest; sec, seconds; TIC, time intensity curve; TNF, tumor necrosis factor; UA, undifferentiated arthritis; 2D/3D, 2 or 3 dimensional; FS, fast initial uptake, then slowly growing; SS, slowly growing; FP, fast initial uptake, then plateauing; Ff1, fast initial uptake, fast wash out (slower); Ff2, fast initial uptake, fast wash out (faster); V, vessel (arterial/venous) enhancement.
the peak time, and the washout slope. Less user dependent methods such as principal component analysis (PCA) have also been used, although these methods do not rely on the use of some predefined classes (or TIC shapes) but identify the classes directly from the data. Because these classes cannot easily be compared with the predefined classes as described in the articles in Table 1, articles making use of component analysis were therefore not included in this review.

In the studies where a pixel by pixel approach was used, it became apparent that lesions are typically characterized by more than one TIC type, something that the ROI approach was not able to highlight.

Besides adding the spatial information and therefore also the visual rendering of the tissue heterogeneity in terms of dynamic behavior, the results of the pixel-by-pixel analysis lend well to the analysis of the statistical distribution of the classes. In Lavini et al and van der Leij et al the ratio between the different types of shapes is used as a possible clinical diagnostic tool. Yuan et al propose a classification method for which tissues are classified on the basis of the predominance of a certain shape. Tissues were then categorized as belonging to any of eight “grades” (0 to 8) according to the predominance of a certain shape, or, conversely, on the tendency to have evenly distributed class types.

Clinical findings
The studies presented in the review (Table 1) vary greatly in set up, purpose, and size of the cohort. Some articles presented extensive patient cohorts and others concentrated on one single pathology.

The majority of the studies presented in Table 1 applied the TIC shape analysis to try and differentiate between different tumors and tumor grading, others used it to investigate the activity of inflammatory processes, and others to assess the effect of drugs. The majority of the studies were done in the musculoskeletal (MSK) system investigating bone tumors, soft tissue tumors, and inflammatory processes (rheumatoid arthritis, synovitis). Other studies included one brain study (glioma), one study in prostate, two in liver, five in the abdomen, three in lungs, two in parotid/salivary glands, and two in the head and neck region.

The conclusions presented are spread across a range of findings; some find the technique valuable in differentiating disease and some draw negative conclusions. Because of the large range of pathologies studied, it is not possible to pool the results. Moreover, each tumor/inflammatory process works differently and it is not easy to generalize one type of behavior in one tissue to the behavior in another tissue. Nevertheless, in the overview in Table 1, it can be seen that all 18 studies investigating cancerous lesions associated a malignant lesion with type Ff, and six of 18 associated it with type FP. Five of 18 studies reported the presence of type FS in malignant lesions, and four of 18 studies reported the presence of type SS, although these were either not predominant, or only seen in a minority of patients. Type O was found to occur in malignancy only in two studies.

Of the 14 studies investigating benign tumors, twelve described either the presence or a prevalence of type SS. The studies that did not associate benign tumors with type SS were describing giant cell tumors (GCT), which were associated with type Ff and FS in three studies. Other benign lesions (besides GCT) were also associated with type Ff and/or FP in, respectively, five and six of eleven cases. Interestingly, both studies investigating the (benign) Warthin tumors reported a type Ff2, making them indistinguishable from malignant lymphomas. Type O was found to occur in benign tumors in four studies.

Metastasis was investigated in two studies, both reporting the presence of more TIC shapes (FP, Ff, FS) in various metastatic nodes. In one study, the correlation between the shape type and microvessel density (MVD) was presented, with the results showing that type Ff correlates with high MVD.

In one article, a patient with osteoporosis was presented and the resulting TIC shape assigned to type FP. Nine papers
report findings in inflammatory processes: arthritis,\textsuperscript{12,35–38} Crohn’s disease,\textsuperscript{39,40} and fistulas.\textsuperscript{41,42} As shown in Table 1, while TIC shape analysis has been applied in a wide range of diseases, it seems to have found more impact in various MSK diseases, where it was widely tested in tumors and arthritis. The most convincing results seem to come from the differentiation of active (rheumatoid) arthritis from controls or from other types of inflammatory processes.\textsuperscript{36,37}

Results from a brain study\textsuperscript{25} have shown that most of the types of shapes occurred in most gliomas, but that the TIC shape analysis, in contrast to PKM analysis, was not able to highlight the effect of antiangiogenic treatment on high grade glioma. This is one of the few examples of work where the TIC shape analysis has been applied in the follow-up of patient treatment. Authors investigating the effect of therapy, ie, Wang et al\textsuperscript{25} (antiangiogenic treatment in liver hepatocellular carcinoma), Lavini et al,\textsuperscript{25} and Ziech et al\textsuperscript{41} (antitumor necrosis factor-alpha in fistulas) agree that the TIC shape does not highlight the effect of the antiangiogenic drugs.

In one other article using TIC analysis, but not using the TIC shape as a diagnostic tool, a change in TIC shape was mentioned.\textsuperscript{44} The authors, who use the steepest slope to monitor response to preoperative chemotherapy in MSK tumors, conclude that steepest slope is not useful for discrimination between benign and malignant tumors due to excessive overlap, but that the TICs they present for two example patients change from a type Ff into a type FS after chemotherapy in one patient, and show a clear type SS in a patient responding well to chemotherapy.

\section*{Discussion}

Literature using TIC shape analysis is growing, but it is still fragmented. Unlike its (twin) application in breast imaging, where authors seem to have agreed on a classification standardization using the three points method,\textsuperscript{14} the TIC shape analysis in other parts of the body seems to present a diversity which makes it extremely challenging to compare the results of the different studies. Nevertheless, a common thread can be found in this diversity: in most publications, malignant processes seem to present, in one way or the other (prevalence or simple occurrence), with a type shape Ff, and most benign lesions present with a prevalence of type SS. Unfortunately, however, the opposite has been observed in certain tumor types where the TIC shape analysis does not yet show enough sensitivity and specificity. Part of this problem has been addressed by adding spatial resolution through the pixel by pixel analysis. In this way, by changing the results derived from a single averaged TIC to mentioning the prevalence or relative ratio of a certain shape and observing the heterogeneity of the distribution,\textsuperscript{23,45} it was seen that malignant lesions (chondrosarcoma), which would have been classified as type SS on an ROI based approach, presented indeed a significant Ff component.\textsuperscript{23}

Most recent studies use the pixel by pixel method, and it is expected that this will soon completely replace the ROI analysis, also as software to perform TIC shape analysis becomes more available.\textsuperscript{46,47} Only in this way will it be possible to approach the sensitivity and specificity of other quantitative techniques, such as PKM.

Certainly another problem has to be addressed, ie, the number of classes used by each study. It is still difficult on the basis of the published studies to assess which classes are truly necessary, or whether there are classes that could be removed. Conversely, it is possible that more classes might have to be added. Works on automatic detection of the classes that “naturally” occur in DCE-MRI datasets are still in progress, for example the work using PCA.\textsuperscript{48}

\section*{Limitations of the TIC shape analysis and dependence on MRI scan parameters}

The TIC shape analysis does not provide absolute measures. It is dependent, although only slightly, on the protocol chosen: the length of the DCE-MRI scan, the time resolution, and the scan parameters (TR/flip angle) can all influence the final shape. Because the T1 weighting of the sequence determines the relationship between signal and contrast agent concentration,\textsuperscript{1} situations where signal saturation occurs due to high contrast agent concentrations should be avoided. If signal saturation occurs (for example due to insufficient T1 weighting), part of the enhancement curve might reach a plateau (type FP) instead of showing an increasing–decreasing pattern (type Fs). This can have an effect on the shape classification, resulting in the same tissue possibly being classified differently when using different protocols. Reproducibility studies in this field would be very welcome.

Partial volume is also a problem in DCE-MRI protocols that privilege time resolution over spatial resolution (voxels can be of the order of 1.5 to 3 millimeters [in plane] and 3 to 6 millimeters in the “slice” direction). The coarse resolution might result in voxels hosting different TIC shape types. As an example, voxels with mixed type V (vessel) and type SS might result in an averaged type Ff. This could be the case in, among others, the synovial membrane which is fed by a neighboring artery. In this case, it is still difficult to discriminate between voxels originating purely from intravascular and extravascular compartments.
Other problems involve the temporal resolution. If insufficient, the arterial/venous type V which is characterized by an early steep slope followed by fast washout might not be recognized at all. Typically, when the contrast agent is injected as a short bolus, the initial peak typically lasts less than 40 seconds.\textsuperscript{49,50} It is to be expected, therefore, that a temporal resolution of less than 40 seconds will not be able to identify the initial enhancement in the vessel.

Despite the advantages of the pixel by pixel approach in terms of sensitivity to spatial heterogeneity, the technique suffers more from the lower signal to noise ratio, as well as from patient movement. The dependence of the automatic classification on pixel size has not been investigated yet. Motion correction has only been used in one article\textsuperscript{60} where the TIC shape analysis (pixel by pixel) was applied in the bowel. The usefulness of motion correction in improving the TIC shape analysis has not been addressed in any of the studies presented here. Furthermore, the dependence of the classification on the particular Gd-based contrast agent has also not been investigated.

**Comparison with pharmacokinetic (PK) analysis**

When compared to the quantitative PK analysis, the advantage of the TIC shape analysis lies predominantly in its simplicity and accessibility. Although PKM has been acknowledged to provide the best MR endpoint for assessing solid tumors, neoangiogenesis, and response to antiangiogenic therapy,\textsuperscript{4} its difficult implementation, involving the extra measurement of the native T1, the calculation of the absolute contrast agent concentrations, as well as an AIF has put off many clinically oriented researchers who still prefer the more heuristic, but more accessible, TIC shape analysis approach. Furthermore, although a correctly implemented PKM analysis can add significant information to the tissue physiology, the chance to implement it incorrectly is not negligible. It is widely acknowledged that a small error in the AIF can propagate in the resulting $K_{\text{trans}}$ and $v_{\text{p}}$ parameters of the PKM in a significant way. In the same way any inaccuracy in the value of the relaxivity and of the T1 will also severely affect the final $K_{\text{trans}}$.\textsuperscript{51} The robustness and reproducibility of the method, therefore, suffers. The TIC shape analysis, on the contrary, is not dependent on any assumption; it only relies on the observation and classification of the raw data.

**Future directions**

The quest to assess the clinical value of the TIC shape is still open. Although the number of applications has grown, there is a need for more focused studies and for a more general consensus on the protocols to be used.

It has been shown that the TIC shape analysis alone might not be able to highlight some effects, such as the antiangiogenic effects of drugs,\textsuperscript{25} and the method might need to be refined to improve its sensitivity.

The necessity of devising a new quantitative non-PKM based analysis method has been widely recognized and new model-free methods continue to appear. Among those, there are methods that continue to rely on the classifications of TIC shapes or on parameters which are derived from them.\textsuperscript{43,48} Guo and Reddick\textsuperscript{52} describe a way of redefining shapes and extracting descriptive parameters from them. They proposed a method called curve pattern analysis (CPA) which is used to generate some “quantitative” CPA parameters, eg, K, beta1, beta2, and beta3, which quantify in some way the TIC shape. These parameters were tested in pediatric osteosarcomas.

Moreover, pure TIC shape analysis has been approached with different image analysis techniques, more independent of operator chosen thresholds. In the last year, a large amount of literature has appeared that makes use of PR techniques to classify DCE-MRI data. PR techniques involve automatic recognition of certain enhancement patterns based on a statistical classifier, which is responsible for decision making to assign a certain pattern to a certain class. Many types of classifiers exist and the literature describes the use of various classifiers for the analysis of DCE-MRI data. Artificial neural networks are used by Kale et al,\textsuperscript{53} Lucht et al,\textsuperscript{54} and Nattkemper et al,\textsuperscript{55} and support vector machines by Levman et al.\textsuperscript{56} A good overview of the methods applied to DCE-MRI can be found in Eyal and Degani.\textsuperscript{41} Most of these works have been carried out in breast lesions.

It is beyond the scope of this review to dwell on the PR techniques and their methodology. Still, it is worth mentioning that significant advances have been made in this field toward an improvement of the classification of DCE-MRI data. Importantly, DCE-MRI generated TIC shapes can be combined with other features, arising for example from anatomical structure, to produce an automatic classification of tissues into malignant and benign. Especially in the field of breast imaging, the works using combined features have reached an advanced stage. New and interesting methods have been proposed, such as textural kinetic analysis.\textsuperscript{57} It is desirable that the new developments in breast DCE-MRI analysis will soon be adapted to the data acquired with higher temporal resolution described in this review, and possibly applied in other diseases.
Conclusion
Because not only the protocols differ greatly in terms of sequence and sequence parameters, and because the classification systems appear so diverse, standardization should eventually be proposed, in a way similar to that established for breast imaging. The effect of standardization will result in easier comparison between studies, and make meta-analysis possible. The key issue as to whether the TIC shape analysis alone can differentiate malignant from benign tumors, or differentiate between tumor grades, remains controversial. Besides the heterogeneous clinical results, the plethora of different names for the different shapes and lack of standardization contribute to the uncertainty. Nevertheless, from this overview we could find agreement that a prevalence of a rapidly growing, rapidly washing out TIC shape remains consistently a mirror of malignancy in tumors and of activity in rheumatoid arthritis, the latter being a pathology where TIC shape analysis seems to be particularly successful. The few studies investigating the effect of drugs did not show the technique to be promising. It is to be hoped that an increase in the use of spatially resolved TIC shape analysis techniques will lead to more insight in the tissue behavior, and that a combination with other analysis techniques might increase its sensitivity.

Disclosure
The authors report no conflict of interest in this work.

References


